

Mylab partners with Ekincare to promote Serum's flu vaccine among corporates

27 November 2023 | News

NASOVAC-S4 is administered through the nasal route, offering a non-invasive and painless alternative to traditional injections

Pune-based startup Mylab has announced a strategic partnership with Ekincare, a corporate wellness and health benefits platform. This collaboration aims to promote NASOVAC-S4, a pioneering influenza nasal vaccine developed by the Serum Institute of India (SII), among corporate entities.

The joint effort between Mylab and Ekincare will enable businesses to incorporate NASOVAC-S4 into their employee wellness programmes. By making this innovative influenza vaccine accessible to their employees, corporations can take proactive measures to safeguard their workforce's health.

Influenza, commonly known as the flu, poses a significant health risk to employees, impacting workforce productivity and overall well-being. The NASOVAC-S4 vaccine offers an advanced and convenient solution to protect employees from influenza and reduce its potential impact on business operations.

NASOVAC-S4 is administered through the nasal route, offering a non-invasive and painless alternative to traditional injections. It includes two influenza Type A virus strains (A/H1N1 and A/H3N2) and two influenza Type B virus strains (Victoria and Yamagata lineage). Its efficacy and ease of administration make it an attractive option for corporate flu vaccination drives.

Through this partnership, Mylab and Ekincare aim to foster a culture of proactive health management within corporate organisations and contribute to reducing the impact of influenza on the workplace.